Alpha Teknova Inc. (TKNO)
TKNO trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1850902/000185090226000002/0001850902-26-000002-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | TKNO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001850902 |
| SEC industry code | In Vitro & In Vivo Diagnostic Substances |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $40.5M |
| Net income | -$17.3M |
| Operating income | -$17.0M |
| Net margin | -42.6% |
| Operating margin | -41.9% |
| Revenue growth | +7.4% |
| Cash | $5.9M |
| Total assets | $103.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 12.1× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $6.6M cash; operating cash flow -$1.4M a quarter. | Report 2026-09-30 |
| Shares outstanding | 62,903,130 (2026-11-04); 53,529,174 a year earlier; 40,727,780 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-10-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, San Jose, California, United States | PCAOB Form AP 2026-03-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $144K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $12.7M | -$3.5M | -$1.3M | $6.6M | $13.3M | $46.0M | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $12.2M | -$3.2M | -$471K | $6.0M | $13.2M | $43.7M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $11.1M | -$4.6M | -$3.4M | $4.3M | $13.2M | $41.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $10.0M | -$4.8M | -$462K | $5.9M | $13.1M | $40.5M | 10-K 2026-03-02 |
| Q3 2025 2025-09-30 | $10.5M | -$4.3M | -$2.0M | $3.2M | $13.1M | $39.8M | 10-Q 2026-11-05 |
| Q2 2025 2025-06-30 | $10.3M | -$3.6M | -$2.1M | $3.3M | $13.0M | $38.9M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $9.8M | -$4.6M | -$4.1M | $3.4M | $13.0M | $38.3M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $9.3M | -$5.7M | -$936K | $3.7M | $9.4M | $37.7M | 10-K 2026-03-02 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-10-21 |
| Latest annual report | 10-K | 2026-03-02 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-04 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 222 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.1% |
| 1 month | -0.1% |
| 3 months | +11.2% |
| Year to date | +116.1% |
| 1 year | +85.3% |
| From 52-week high | -12.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MYGN | Myriad Genetics Inc. | $5.57 | -1.59% | $534.3M |
| NNNN | Anbio Biotechnology | $3.88 | +1.57% | $558.3M |
| QUIT | Achieve Life Sciences Inc. Common Shares | $6.06 | -4.11% | $666.8M |
| QDEL | QuidelOrtho Corporation | $10.21 | -4.93% | $700.5M |
| NTLA | Intellia Therapeutics Inc. | $9.86 | +1.65% | $1.4B |
| CLDX | Celldex Therapeutics Inc. | $28.59 | -0.83% | $2.2B |
| ICCC | ImmuCell Corporation | $11.42 | +6.23% | $103.8M |
| NEOG | Neogen Corporation | $10.88 | -3.12% | $2.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier